Starpharma Holdings

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Trading Performance

Weighted Moving Average

Score

0.3

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 24 16.5 0.21% 0.26% 19.4% -2.6% 48.3%
SHORT 24 14.3 0.29% 0.41% 6.7% -3.1% -5.9%

Summary

Technical Analysis

Starpharma Holdings (SPL.AX)


Indicator:

WEIGHTED MOVING AVERAGE


Last Signal:

BEARISH


Trading: SELL @ $1.34
Signal Strength: STRONG
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.


Starpharma Holdings (ASX:SPL) currently has a confirmed downtrend. Recent trading has caused the WMA 15 day average to move below the closing price confirming the short term trend following indicator. Currently, the return on WMA15 is 0.8%.



Weighted moving averages (WMA) are difficult to construct but more reliable than the simple moving averages. WMA permits an unequal weighting on prior time periods.

Calculation: Weighted Moving Average (WMA):
1) Ft= W1At-1 + WnAt-n


PROFILE: Starpharma Holdings (SPL.AX)


Stock Exchange: ASX
Company: Starpharma Holdings
Ticker Codes: | SPL.AX | ASX:SPL |

About Starpharma Holdings (ASX:SPL):

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications primarily in Australia and Canada. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections. It also develops dendrimer-enhanced, or DEP versions of existing drugs, including DEP docetaxel that is in Phase I clinical trial for breast, prostate, lung, and ovarian tumor. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Top 10:

Weighted Moving Average

Download
Company Close Change(%) Volume Value Signal
RSG Resolute Mining 1.74 7.1 9,161,059 6.4 BULLISH
PRU Perseus Mining 0.71 6.8 12,414,565 3 BULLISH
MLX Metals X 0.25 6.4 2,769,031 7.9 BULLISH
AQG Alacer Gold Corp 5.42 6.3 936,317 6 BULLISH
OMH OM Holdings 0.86 5.5 28,581 8.7 BULLISH
SBM St Barbara Mines 3.55 5.3 5,019,351 1.2 BULLISH
AGG Anglogold Ashanti 5.56 5.1 467,306 21.4 BULLISH
RRL Regis Resources 6.38 4.9 5,376,386 1.2 BULLISH
URF Us Masters Residential Property Fund 0.9 4.7 25,678 0.3 BULLISH
NUF Nufarm 4.58 4.3 2,537,812 1.8 BULLISH